

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
Date Submitted: DEC 01 2005

(use as many sheets as necessary)

Sheet 1 of 2

Complete if Known

| | |
|------------------------|-----------------|
| Application Number | 10/553,298 |
| Filing Date | 10/14/2005 |
| First Named Inventor | Nicholas BARDEN |
| Group Art Unit | Unassigned |
| Examiner Name | Unassigned |
| Attorney Docket Number | 028622-0137 |

U.S. PATENT DOCUMENTS

| Examiner Initials* | Cite No. ¹ | U.S. Patent Document | | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document MM-DD-YYYY | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
|--------------------|-----------------------|----------------------|-----------------------------------|---|---|---|
| | | Number | Kind Code ² (if known) | | | |
| | A1 | 2004/0229262 | A1 | FRANCO et al. | 11/18/2004 | |
| | A2 | 6,214,581 | B1 | LYNCH et al. | 04/10/2001 | |

FOREIGN PATENT DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Foreign Patent Document | | | Name of Patentee or Applicant of Cited Documents | Date of Publication of Cited Document MM-DD-YYYY | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T ⁶ |
|--------------------|-----------------------|-------------------------|---------------------|-----------------------------------|--|---|---|----------------|
| | | Office ³ | Number ⁴ | Kind Code ⁵ (if known) | | | | |
| | A3 | EP | 1199372 | A2 | ASTRAZENECA AB | 04/24/2002 | | |
| | A4 | EP | 1310493 | A1 | PFIZER PRODUCTS, INC. | 05/14/2003 | = A8 | |
| | A5 | WO | 99/55901 | A | ABBOTT LABORATORIES | 11/04/1999 | | |
| | A6 | WO | 01/44213 | A | ASTRAZENECA AB | 06/21/2001 | | |
| | A7 | WO | 01/62787 | A1 | OXFORD GLYCOSCIENCES (UK) LIMITED | 08/30/2001 | | |
| | A8 | WO | 03/42190 | A | PFIZER PRODUCTS INC. | 05/22/2003 | = A4 | |

NON PATENT LITERATURE DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ⁶ |
|--------------------|-----------------------|--|----------------|
| | A9 | BURNSTOCK, Geoffrey, "Introduction: P2 Receptors," Current Topics in Medicinal Chemistry, Vol. 4, 2004, pp. 793-803. | |
| | A10 | HUMPHREYS et al., "Isoquinolines as Antagonists of the P2X ₇ Nucleotide Receptor: High Selectivity for the Human versus Rat Receptor Homologues," Molecular Pharmacology, Vol. 54, 1998, pp. 22-32. | |
| | A11 | LIU et al., "Technological Advances in High-Throughput Screening," Am. J. Pharmacogenomics, Vol. 4, No. 4, 2004, pp. 263-276. | |
| | A12 | MUZNY et al., "Homo sapiens 12 BAC RP 11-946P6 (Roswell Park Cancer Institute BAC Library) complete sequence," December 2, 2002, XP002284283 (Database EMBL, 5/14/1999; Database Accession No. AC007546). | |
| | A13 | NORTH et al., "Pharmacology of clones P2X receptors," Annual Review of Pharmacology and Toxicology, Vol. 40, 2000, pp. 563-580. | |
| | A14 | SANZ et al., "Tenidap enhances P2Z/P2X ₇ receptor signaling in macrophages," European Journal of Pharmacology, Vol. 355, 1998, pp. 235-244. | |
| | A15 | SILVERMAN, Richard B., The Organic Chemistry of Drug Design and Drug Action, Second Edition, Elsevier Academic Press, Chapter 2, pp. 7-120. | |
| | A16 | WILLIAMS, Michael, "Purinergic Drugs: Opportunities in the 1990s," Drug Development Research, Vol. 28, 1993, pp. 438-444. | |

Examiner
Signature

/Michael Pak/

Date
Considered

01/05/2009

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.